Oncogene Associated cDNA Microarray Analysis Shows PRAME Gene Expression is a Marker for Response to Anthracycline Containing Chemotherapy in Patients with Diffuse Large B-cell Lymphoma

• Kawano Riko

  First Department of Internal Medicine, School of Medicine Department of Pathology, School of Medicine, Kurume University

• Karube Kennosuke

  Department of Pathology, School of Medicine, Kurume University

• Kikuchi Masahiro

  Department of Pathology, School of Medicine, Fukuoka University

• Takeshita Morishige

  Department of Pathology, School of Medicine, Fukuoka University

• Tamura Kazuo

  First Department of Internal Medicine, School of Medicine

• Uike Naokuni

  Department of Hematology National Kyushu Cancer Center

• Eto Tetsuya

  Department of Hematology Hamanomachi Hospital

• Ohshima Koichi

  Department of Pathology, School of Medicine, Kurume University

• Suzumiya Junji

  First Department of Internal Medicine, School of Medicine Second Department of Internal Medicine, Fukuoka University Chikushi Hospital

抄録

CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) therapy achieves a response in more than 60% patients with diffuse large B-cell lymphomas (DLBCLs). However, DLBCL shows a heterogeneous response to chemotherapy, and some patients are refractory to CHOP therapy. This difference in response to therapy is most likely due to differences in biological characteristics. We used cDNA microarray analysis to identify genes differentially expressed in anthracycline containing chemotherapy-resistant DLBCLs (7 patients) compared with anthracycline containing chemotherapy-sensitive DLBCLs (6 patients). Nine genes on the cDNA chip showed increased expression in anthracycline containing chemotherapy-resistant patients. We chose the preferentially expressed antigen of melanoma (PRAME) gene because it showed the highest expression in anthracycline containing chemotherapy-resistant DLBCLs on the cDNA chip, and it has been linked to prognosis of hematological malignancies. We also examined the relationship between PRAME gene expression and progression-free survival (PFS) in 45 patients with DLBCL. The progression-free survival of PRAME-positive patients (n=12) was significantly worse than that of PRAME-negative patients (n=33) (p=0.0373). Our results therefore indicate that PRAME expression in DLBCL correlates with response to anthracycline containing chemotherapy. [J Clin Exp Hematopathol 49(1) : 1-7, 2009]

収録刊行物

• Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ

  Ｊｏｕｒｎａｌ　ｏｆ　Ｃｌｉｎｉｃａｌ　ａｎｄ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ 49 (1), 1-7, 2009

  日本リンパ網内系学会

キーワード

• diffuse large B-cell lymphoma
• anthracycline containing chemotherapy resistant
• <I>preferentially expressed antigen of melanoma</I> (<I>PRAME</I>) gene

詳細情報

• CRID: 1390001204701458048
• NII論文ID: 10025683555
• NII書誌ID: AA11556796
• DOI: 10.3960/jslrt.49.1
• ISSN: 18809952
• ISSN: 13464280
• Web Site: https://search.jamas.or.jp/link/ui/2009344724
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可